topic

848 Predictions of endogenous neoantigens from varied genomic sources in a syngeneic murine cancer model
Wolfgang Beckabir, Misha Fini, Steven Vensko, Jessica Alley, Maria Sambade, Andrew Truong, Mi Zhou, William Kim, Benjamin Vincent

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A946-A947; DOI: 10.1136/jitc-2023-SITC2023.0848
849 Snail mucus increases the anti-cancer activity of anti-PD-L1 antibody in melanoma
Bo-Rong Chen, Wei-Chien Huang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A948; DOI: 10.1136/jitc-2023-SITC2023.0849
850 Selective expansion of anti-tumor CD4 T-cell subsets contributes to oncolytic virotherapeutic efficacy in malignant glioma
Jeffrey M Grimes, Jianmei W Leavenworth

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A949; DOI: 10.1136/jitc-2023-SITC2023.0850
851 Enhancing cancer immunotherapy with Deinococcus geothermalis in combination with PD-1 inhibitors: a novel strategy for non-small cell lung cancer treatment
Sheng Li, Bo Jia, Jianjie Li, Yuling He, Ziping Wang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A950; DOI: 10.1136/jitc-2023-SITC2023.0851
852 Modified-epitope-based vaccine (OSE2101) combined with anti-PD-1/IL-7v bispecific antibody sustains long-lasting tumor specific antigen memory T cell response in vivo
Belarif Lyssia, Julien Taurelle, Ariane Desselle, Justine Durand, Margaux Seite, Caroline Mary, Geraldine Teppaz, Virginie Thepenier, Cecile Batty, Berangere Vasseur, Thomas Vandewalle, Laurie Cordonnier, Aurore Morello, Nicolas Poirier

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A951; DOI: 10.1136/jitc-2023-SITC2023.0852
853 Evofosfomide potentiates the efficacy of a novel anti-PD-L1/PD-L2 monoclonal antibody against immune excluded tumors
Ahmad Salameh, Paul Blezinger, Christine Gagliardi, Matt Hemberger, James Barlow, Michael Curran, Federica Pericle

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A952; DOI: 10.1136/jitc-2023-SITC2023.0853
854 Glutamine blockade and anti-PD1 treatment reprograms the tumor infiltrating myeloid cells in mouse model of soft tissue sarcomas
Aditya Suru, Alexandre Maalouf, Liang Zhao, Ada Tam, Lindy Zhang, Michele Doucet, Marwa Islam, Zahra Jamil, Christian Meyer, Carol Morris, Adam Levin, John Gross, Sophia A Strike, Jonathan Greer, Fabian Johnston, Daniel Rhee, Brian Ladle, Sudipto Ganguly, Robert Anders, Drew Pardoll, Nicolas Llosa

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A953; DOI: 10.1136/jitc-2023-SITC2023.0854
855 Unleashing an approach to expand antigen-specific immune response via synergistic integration of photothermal therapy and FlaB-Her2 vaccination in a DD-her2/neu mice orthotopic breast cancer model
Jayalakshmi Thiruppathi, Veena Vijayan, Yong Jun Bang, Hye Suk Hwang, Inkyu Park, Shee Eun Lee, Joon Haeng Rhee

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A954; DOI: 10.1136/jitc-2023-SITC2023.0855
857 Dose- and time-dependent immune cell dynamics in irradiated gliomas
Dennis A Agardy, Julius Michel, Berin Boztepe, Jessica Hunger, Niklas Kehl, Alexandros Kourtesakis, Julia Geller, Yu-Chan Chih, Kristine Jähne, Viktoria Sachs, Manuel Fischer, Michael Breckwoldt, Wolfgang Wick, Theresa Bunse, Lukas Bunse, Michael Platten

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A955; DOI: 10.1136/jitc-2023-SITC2023.0857
858 Breaking through the resistance of breast cancer to immune checkpoint blockers in a unique mouse model of HR+ disease
Norma Bloy, Aitziber Buqué, Cristina Iribarren, Claudia Galassi, Giulia Petroni, Takahiro Yamazaki, Ai Sato, Silvia Formenti, Lorenzo Galluzzi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A956; DOI: 10.1136/jitc-2023-SITC2023.0858

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages